Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/adt.2025.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in neuroimaging of Alzheimer's disease and related dementias.
Alzheimers Dement
September 2025
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
This review covers recent advances (2023-2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain.
View Article and Find Full Text PDFKappa Free Light Chain Index in the Real World-Do We Miss Clinically Relevant Information by Skipping Oligoclonal Banding?
Eur J Neurol
September 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Background: No standardized strategy for integrating κ-free light chain (κ-FLC) index into routine cerebrospinal fluid (CSF) diagnostics has yet been established.
Objective: To determine agreement between κ-FLC index and CSF-restricted oligoclonal bands (OCB), and to identify κ-FLC index range where second-line OCB testing is needed.
Methods: A retrospective analysis was conducted in patients who had κ-FLC measurement between December 2023 and December 2024 at the Medical University of Innsbruck.
Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.
Clin Nucl Med
September 2025
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea.
Background: Alzheimer disease (AD) is characterized by amyloid-β plaques (A), tau tangles (T), and neurodegeneration (N), collectively defining the ATN framework. While imaging biomarkers are well-established, the prognostic value of plasma biomarkers in predicting cognitive decline remains underexplored. This study compares plasma and imaging A/T/N biomarkers in predicting cognitive decline and evaluate the impact of combining biomarkers across modalities.
View Article and Find Full Text PDFRelapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?
Mult Scler J Exp Transl Clin
September 2025
Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.
Objectives: To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.
Methods: In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks.
Early downregulation of hair cell (HC)-specific genes in the vestibular sensory epithelium during chronic ototoxicity.
J Biomed Sci
September 2025
Laboratori 4106, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Feixa Llarga S/N, 08907, Hospitalet de Llobregat, Catalunya, Spain.
Background: Exposure of mammals to ototoxic compounds causes hair cell (HC) loss in the vestibular sensory epithelia of the inner ear. In chronic exposure models, this loss often occurs by extrusion of the HC from the sensory epithelium towards the luminal cavity. HC extrusion is preceded by several steps that begin with detachment and synaptic uncoupling of the cells from the afferent terminals of their postsynaptic vestibular ganglion neurons.
View Article and Find Full Text PDF